Targeted therapies for renal cell carcinoma: understanding their impact on survival

Area of Science:

• Oncology
• Clinical Trials
• Pharmacology

Background:

• The US FDA has approved six targeted agents for metastatic renal cell carcinoma (mRCC) in the last five years.
• This expansion of treatment options presents challenges for oncologists in selecting appropriate therapies for individual patients.

Purpose of the Study:

• To analyze the study designs of pivotal clinical trials for recently approved mRCC targeted agents.
• To discuss the appropriate use of comparator arms (e.g., interferon-alpha, placebo) in targeted therapy trials.
• To evaluate the merits of progression-free survival (PFS) versus overall survival (OS) as primary endpoints and address their potential lack of correlation.

Main Methods:

• Detailed analysis of study designs from pivotal trials for six targeted mRCC agents.
• Examination of comparator arm selection in these trials.
• Discussion on interpreting overall survival (OS) considering post-study therapies and crossover designs.

Main Results:

• The analysis highlights the importance of understanding trial methodologies for applying targeted therapies in mRCC.
• Progression-free survival (PFS) and overall survival (OS) may not be directly correlated, necessitating careful interpretation.
• Head-to-head trials are essential to resolve clinical equipoise among approved targeted agents.

Conclusions:

• Oncologists require a thorough understanding of clinical trial data to effectively utilize new mRCC targeted agents.
• Interpreting survival endpoints, particularly OS, requires consideration of confounding factors like post-study treatments.
• Future research should focus on head-to-head comparisons of targeted therapies to guide clinical decision-making in mRCC.